Our Responsibility
Our Responsibility
Search
Victor Emenike
Victor Emenike is a data scientist in operations, specifically in the launch and innovation organization, feels valued and supported in new ideas.
Life forward - Boehringer Ingelheim unveils its evolved company brand
Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Digital Clinical Support Tool Aims to Individualize Guidelines-Based Diabetes Care
BURLINGTON, ON – October 11, 2023 – Boehringer Ingelheim (Canada) Ltd. and BI X, the digital lab of Boehringer Ingelheim, have collaborated to introduce a new digital clinical support tool for Canadian healthcare professionals managing the care
Purchasing
Purchasing at Boehringer Ingelheim
Mental Disorders
Mental Disorders
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Business Ethics
The ethical principles that have guided Boehringer Ingelheim for 130 years created a culture of corporate and social responsibility and commitment.
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
Albertans living with chronic conditions benefit from home monitoring
Albertans living with chronic conditions benefit from home monitoring
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Virtual care pharmacy services offered in Alberta long-term care facilities
Virtual care pharmacy services offered in Alberta long-term care facilities
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Scam Alert
Scam Alert
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Speak Up
The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Strategies for overcoming resistance in parasites
Strategies for overcoming resistance in parasites
Equine asthma: Recognizing and managing respiratory issues in horses
Equine asthma: Recognizing and managing respiratory issues in horses
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner
Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner